Fractyl Q2 net loss $25.5M; REMAIN-1 data show 84% weight-loss maintenance

FRACTYL HEALTH, INC.

Net loss $25.5M vs $27.9M YoY; R&D down to $13.8M from $21.2M.
Cash $47.1M at 6/30/26; runway into early 2027, beyond pivotal readout.
REMAIN-1 Midpoint: Revita patients maintained 84% of weight loss vs 46% sham (optimized subgroup).
REVEAL-1: ~78% weight-loss maintenance after single Revita; no serious device-related AEs.
Pivotal topline due early Q4 2026; potential FDA De Novo submission late Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.